
Calico Life Sciences, a clinical-stage biotechnology organisation focused on aging and age-related diseases and founded by Alphabet and Arthur D Levinson, has announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to fosigotifator, an investigational eIF2B activator being evaluated for the treatment of Vanishing White Matter (VWM).
The designation was granted based on early clinical data from Calico’s ongoing phase 1b/2 clinical study (2023-505704-30-00) evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of fosigotifator in people with VWM.
The PRIME scheme is designed to provide enhanced support for the development of medicines that target conditions with an unmet medical need, for which no treatment option exists, or where they can offer a major therapeutic advantage over existing treatments. To be eligible for PRIME designation, a product candidate must show its potential to benefit patients with unmet medical needs based on early clinical data or on compelling non-clinical data and tolerability data from initial clinical trials.
The designation follows the US Food and Drug Administration’s granting of breakthrough therapy designation for fosigotifator earlier this year and builds on the programme’s prior selection for the FDA’s support for clinical trials advancing rare disease therapeutics pilot programme. These designations do not guarantee that fosigotifator will be approved.


